Fig. 5From: A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancerHematologic toxicity of DCB:TLZ and nano-cocktail nDCB:nTLZ assessed by A WBC, B RBC, and C PLT count. Representative slices of kidneys, livers, and spleens D stained with H&E demonstrate no gross morphological organ damageBack to article page